NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO
Post# of 154440
(Total Views: 273)
Posted On: 11/13/2018 4:31:39 PM
NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 HIV Monotherapy Trial Shows Promising Results
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning provided an update on its PRO 140 (leronlimab) as a single agent for maintenance of HIV viral load suppression. Per the update, approximately 92 percent of newly enrolled patients administered PRO 140 in a 700 mg dosage as part of the CD03 Phase 3 investigative monotherapy trial have achieved viral load suppression. Patients enrolled in the Phase 3 monotherapy trial were prescreened for CCR5-tropic HIV-1 infection and treated for up to 12 weeks.
“Our analysis of data indicate that patients treated with PRO 140 700 mg dose who achieve suppressed viral load at the six-week mark are highly likely to continue to maintain suppressed viral load,” CytoDyn president and CEO Nader Pourhassan, Ph.D., stated in the news release. “Given these promising data (92% responder rate), we plan to submit a pivotal monotherapy trial protocol for PRO 140 as a single-agent maintenance therapy before the end of 2018 with the intention of filing for a label expansion subject to combination therapy’s first approval.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning provided an update on its PRO 140 (leronlimab) as a single agent for maintenance of HIV viral load suppression. Per the update, approximately 92 percent of newly enrolled patients administered PRO 140 in a 700 mg dosage as part of the CD03 Phase 3 investigative monotherapy trial have achieved viral load suppression. Patients enrolled in the Phase 3 monotherapy trial were prescreened for CCR5-tropic HIV-1 infection and treated for up to 12 weeks.
“Our analysis of data indicate that patients treated with PRO 140 700 mg dose who achieve suppressed viral load at the six-week mark are highly likely to continue to maintain suppressed viral load,” CytoDyn president and CEO Nader Pourhassan, Ph.D., stated in the news release. “Given these promising data (92% responder rate), we plan to submit a pivotal monotherapy trial protocol for PRO 140 as a single-agent maintenance therapy before the end of 2018 with the intention of filing for a label expansion subject to combination therapy’s first approval.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)